An Exercise in Extrapolation: Clinical Management of Atypical CML, MDS/MPN-Unclassifiable, and MDS/MPN-RS-T
- 24 September 2016
- journal article
- review article
- Published by Springer Nature in Current Hematologic Malignancy Reports
- Vol. 11 (6) , 425-433
Abstract
According to the recently published 2016 World Health Organization (WHO) classification of myeloid malignancies, myelodysplastic/myeloproliferative neoplasms (MDS/MPN) include atypical chronic myeloid leukemia (aCML), MDS/MPN-unclassifiable (MDS/MPN-U), chronic myelomonocytic leukemia (CMML), juvenile myelomonocytic leukemia (JMML), and MDS/MPN ring sideroblasts with thrombocytosis (MDS/MPN-RS-T). MDS/MPN-RS-T was previously a provisional category known as refractory anemia with ring sideroblasts with thrombocytosis (RARS-T) which has now attained a distinct designation in the 2016 WHO classification. In this review, we focus on biology and management of aCML, MDS/MPN-U, and MDS/MPN-RS-T. There is considerable overlap between these entities which we attempt to further elucidate in this review. We also discuss recent advances in the field of molecular landscape that further defines and characterizes this heterogeneous group of disorders. The paucity of clinical trials available secondary to unclear pathogenesis and rarity of these diseases makes the management of these entities clinically challenging. This review summarizes some of the current knowledge of the molecular pathogenesis and suggested treatment guidelines based on the available data.Keywords
This publication has 48 references indexed in Scilit:
- The new genetics of chronic neutrophilic leukemia and atypical CML: implications for diagnosis and treatmentBlood, 2013
- OncogenicCSF3RMutations in Chronic Neutrophilic Leukemia and Atypical CMLNew England Journal of Medicine, 2013
- SETBP1 mutations occur in 9% of MDS/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutationsLeukemia, 2013
- Age, JAK2V617F and SF3B1 mutations are the main predicting factors for survival in refractory anaemia with ring sideroblasts and marked thrombocytosisLeukemia, 2013
- Refractory Anemia with Ring Sideroblasts Associated with Marked Thrombocytosis Complicated by Massive Splenomegaly Treated with Lenalidomide Resulting in Resolution of Splenomegaly but Severe and Prolonged PancytopeniaCase Reports in Hematology, 2013
- Biologic and clinical significance of somatic mutations of SF3B1 in myeloid and lymphoid neoplasmsBlood, 2013
- Recurrent SETBP1 mutations in atypical chronic myeloid leukemiaNature Genetics, 2012
- Clinical features and course of refractory anemia with ring sideroblasts associated with marked thrombocytosisHaematologica, 2012
- SomaticSF3B1Mutation in Myelodysplasia with Ring SideroblastsNew England Journal of Medicine, 2011
- Outcome of hematopoietic stem cell transplantation in patients with atypical chronic myeloid leukemiaBone Marrow Transplantation, 2004